VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q80802491 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233204.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q80802491‏
024 ‎‡a 0000-0001-8865-2684‏ ‎‡2 orcid‏
024 ‎‡a 7401787782‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q80802491‏
100 0 ‎‡a C O Rodriguez‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a C O Rodriguez‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.‏
670 ‎‡a Author's Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs‏
670 ‎‡a Author's Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.‏
670 ‎‡a Author's CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.‏
670 ‎‡a Author's Clinical characteristics and outcome in dogs with splenic marginal zone lymphoma‏
670 ‎‡a Author's Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992-2008)‏
670 ‎‡a Author's Clinical outcome in 94 cases of dermal haemangiosarcoma in dogs treated with surgical excision: 1993-2007*.‏
670 ‎‡a Author's Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.‏
670 ‎‡a Author's Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.‏
670 ‎‡a Author's Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.‏
670 ‎‡a Author's Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma.‏
670 ‎‡a Author's Immunohistochemical and histomorphometric evaluation of vascular distribution in intact canine cranial cruciate ligament.‏
670 ‎‡a Author's Immunohistochemical characterization of feline mast cell tumors.‏
670 ‎‡a Author's Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.‏
670 ‎‡a Author's Mechanisms for T-cell selective cytotoxicity of arabinosylguanine‏
670 ‎‡a Author's Outcome in dogs with surgically resected oral fibrosarcoma‏
670 ‎‡a Author's Outcome in dogs with surgically resected oral fibrosarcoma (1997-2008).‏
670 ‎‡a Author's Paraneoplastic hypertrophic osteopathy in 30 dogs‏
670 ‎‡a Author's Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.‏
670 ‎‡a Author's Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.‏
670 ‎‡a Author's Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand‏
670 ‎‡a Author's Treatment of canine osseous tumors with photodynamic therapy: a pilot study.‏
670 ‎‡a Author's Vascular distribution in ruptured canine cranial cruciate ligament.‏
909 ‎‡a (scopus) 7401787782‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000188652684‏ ‎‡9 1‏
919 ‎‡a mechanismsfortcellselectivecytotoxicityofarabinosylguanine‏ ‎‡A Mechanisms for T-cell selective cytotoxicity of arabinosylguanine‏ ‎‡9 1‏
919 ‎‡a longtermsurvivalindogswithlocalizedhistiocyticsarcomatreatedwithccnuasanadjuvanttolocaltherapy‏ ‎‡A Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.‏ ‎‡9 1‏
919 ‎‡a immunohistochemicalcharacterizationoffelinemastcelltumors‏ ‎‡A Immunohistochemical characterization of feline mast cell tumors.‏ ‎‡9 1‏
919 ‎‡a immunohistochemicalandhistomorphometricevaluationofvasculardistributioninintactcaninecranialcruciateligament‏ ‎‡A Immunohistochemical and histomorphometric evaluation of vascular distribution in intact canine cranial cruciate ligament.‏ ‎‡9 1‏
919 ‎‡a identificationofsurvivinaninhibitorofapoptosisincanineurinarybladdertransitionalcellcarcinoma‏ ‎‡A Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma.‏ ‎‡9 1‏
919 ‎‡a fluoroquinolonemediatedinhibitionofcellgrowthsg21000cellcyclearrestandapoptosisincanineosteosarcomacelllines‏ ‎‡A Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.‏ ‎‡9 1‏
919 ‎‡a evaluationofanextractionlesshighperformanceliquidchromatographytandemmassspectrometrymethodfordetectionandquantitationofrosiglitazoneincanineplasma‏ ‎‡A Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.‏ ‎‡9 1‏
919 ‎‡a establishmentofadogmodelforthep53familypathwayandidentificationofanovelisoformofp21cyclindependentkinaseinhibitor‏ ‎‡A Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.‏ ‎‡9 1‏
919 ‎‡a clinicaloutcomein94casesofdermalhaemangiosarcomaindogstreatedwithsurgicalexcision19932007‏ ‎‡A Clinical outcome in 94 cases of dermal haemangiosarcoma in dogs treated with surgical excision: 1993-2007*.‏ ‎‡9 1‏
919 ‎‡a clinicalcharacteristicstreatmentandoutcomeofdogswithpresumedprimaryhepaticlymphoma18cases1992‏ ‎‡A Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992-2008)‏ ‎‡9 1‏
919 ‎‡a clinicalcharacteristicsandoutcomeindogswithsplenicmarginalzonelymphoma‏ ‎‡A Clinical characteristics and outcome in dogs with splenic marginal zone lymphoma‏ ‎‡9 1‏
919 ‎‡a chopchemotherapyforthetreatmentofcaninemulticentrictcelllymphoma‏ ‎‡A CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.‏ ‎‡9 1‏
919 ‎‡a carboplatinversusalternatingcarboplatinanddoxorubicinfortheadjuvanttreatmentofcanineappendicularosteosarcomaarandomizedphase3trial‏ ‎‡A Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.‏ ‎‡9 1‏
919 ‎‡a aerosolgemcitabinepreclinicalsafetyandinvivoantitumoractivityinosteosarcomabearingdogs‏ ‎‡A Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs‏ ‎‡9 1‏
919 ‎‡a phase2clinicaltrialofvinorelbineindogswithcutaneousmastcelltumors‏ ‎‡A A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.‏ ‎‡9 1‏
919 ‎‡a sequentiallowdoseratehalfbodyirradiationandchemotherapyforthetreatmentofcaninemulticentriclymphoma‏ ‎‡A Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.‏ ‎‡9 1‏
919 ‎‡a outcomeindogswithsurgicallyresectedoralfibrosarcoma1997‏ ‎‡A Outcome in dogs with surgically resected oral fibrosarcoma (1997-2008).‏ ‎‡9 1‏
919 ‎‡a targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand‏ ‎‡A Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand‏ ‎‡9 1‏
919 ‎‡a treatmentofcanineosseoustumorswithphotodynamictherapyapilotstudy‏ ‎‡A Treatment of canine osseous tumors with photodynamic therapy: a pilot study.‏ ‎‡9 1‏
919 ‎‡a vasculardistributioninrupturedcaninecranialcruciateligament‏ ‎‡A Vascular distribution in ruptured canine cranial cruciate ligament.‏ ‎‡9 1‏
919 ‎‡a phase12clinicaltrialof2difluoromethylornithinedfmoandanovelpolyaminetransportinhibitormqt1426forfelineoralsquamouscellcarcinoma‏ ‎‡A Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.‏ ‎‡9 1‏
919 ‎‡a paraneoplastichypertrophicosteopathyin30dogs‏ ‎‡A Paraneoplastic hypertrophic osteopathy in 30 dogs‏ ‎‡9 1‏
919 ‎‡a outcomeindogswithsurgicallyresectedoralfibrosarcoma‏ ‎‡A Outcome in dogs with surgically resected oral fibrosarcoma‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2008‏ ‎‡9 2‏
996 ‎‡2 BNE|XX4685384‏
996 ‎‡2 BNCHL|10000000000000000013886‏
996 ‎‡2 LC|nr 93042413‏
996 ‎‡2 SUDOC|084661631‏
996 ‎‡2 BNE|XX5619209‏
996 ‎‡2 SUDOC|033308004‏
996 ‎‡2 SUDOC|082300372‏
996 ‎‡2 ISNI|0000000028453862‏
996 ‎‡2 PLWABN|9810637722205606‏
996 ‎‡2 ISNI|000000012054904X‏
996 ‎‡2 LC|no2009062877‏
996 ‎‡2 LC|no2004015143‏
996 ‎‡2 BNCHL|10000000000000000272674‏
996 ‎‡2 BNE|XX1517243‏
996 ‎‡2 LIH|LNB:DT73;=0L‏
996 ‎‡2 LC|n 93028900‏
996 ‎‡2 BNE|XX891172‏
996 ‎‡2 ISNI|0000000068610973‏
996 ‎‡2 BNC|981058612038006706‏
996 ‎‡2 KRNLK|KAC2022D1198‏
996 ‎‡2 ISNI|0000000498034531‏
996 ‎‡2 LC|no2019181031‏
996 ‎‡2 LC|n 2001084389‏
996 ‎‡2 SZ|172832187‏
996 ‎‡2 ISNI|0000000059255068‏
996 ‎‡2 BNCHL|10000000000000000118604‏
996 ‎‡2 ISNI|0000000049723155‏
996 ‎‡2 BNCHL|10000000000000000118600‏
996 ‎‡2 ISNI|0000000060256869‏
996 ‎‡2 DNB|1056627476‏
996 ‎‡2 BNE|XX874394‏
996 ‎‡2 LC|n 2002033278‏
996 ‎‡2 ISNI|0000000077241911‏
996 ‎‡2 ISNI|0000000059985984‏
996 ‎‡2 ISNI|0000000071401355‏
996 ‎‡2 BNE|XX5533859‏
996 ‎‡2 LC|n 2015033392‏
996 ‎‡2 ISNI|0000000072105013‏
996 ‎‡2 DNB|13022071X‏
996 ‎‡2 ISNI|0000000031418742‏
996 ‎‡2 BNE|XX5618009‏
996 ‎‡2 ISNI|0000000069758283‏
996 ‎‡2 ISNI|0000000118848622‏
996 ‎‡2 RERO|A014080341‏
996 ‎‡2 ISNI|0000000397151712‏
996 ‎‡2 CAOONL|ncf13703810‏
996 ‎‡2 DNB|1278916253‏
996 ‎‡2 SUDOC|243123531‏
996 ‎‡2 BNE|XX5400008‏
996 ‎‡2 BNE|XX5538350‏
996 ‎‡2 BNE|XX906316‏
996 ‎‡2 BNF|12037682‏
996 ‎‡2 SUDOC|103665722‏
996 ‎‡2 BNE|XX833926‏
996 ‎‡2 LC|n 2003039927‏
996 ‎‡2 LC|n 93040690‏
996 ‎‡2 BNE|XX1040290‏
996 ‎‡2 DNB|1269707264‏
996 ‎‡2 ISNI|0000000042280793‏
996 ‎‡2 LC|no2001075967‏
996 ‎‡2 LC|no2016112377‏
996 ‎‡2 ISNI|0000000095711569‏
996 ‎‡2 BNC|981058614050206706‏
996 ‎‡2 BNE|XX953350‏
996 ‎‡2 DNB|1057513687‏
996 ‎‡2 SUDOC|250483998‏
996 ‎‡2 DNB|1033001325‏
996 ‎‡2 J9U|987007461704005171‏
996 ‎‡2 BNF|13746992‏
996 ‎‡2 LC|no2011084036‏
996 ‎‡2 BNE|XX1143458‏
996 ‎‡2 BIBSYS|2018111‏
996 ‎‡2 DNB|1154418537‏
996 ‎‡2 SUDOC|258415606‏
996 ‎‡2 LC|ns2017003391‏
996 ‎‡2 KRNLK|KAC201858664‏
996 ‎‡2 BNC|981058530338806706‏
996 ‎‡2 BNE|XX856646‏
996 ‎‡2 RERO|A002959081‏
996 ‎‡2 LC|ns2023002597‏
996 ‎‡2 BNC|981058515383906706‏
996 ‎‡2 DNB|1324505958‏
996 ‎‡2 ISNI|0000000059360220‏
996 ‎‡2 LC|ns2012000216‏
996 ‎‡2 BNE|XX923322‏
996 ‎‡2 BNC|981060035571506706‏
996 ‎‡2 BNC|981058516815706706‏
996 ‎‡2 BNE|XX5828137‏
996 ‎‡2 ISNI|0000000060094476‏
996 ‎‡2 BNE|XX1716355‏
996 ‎‡2 ISNI|0000000050191520‏
996 ‎‡2 LC|n 93090193‏
996 ‎‡2 DNB|1169351786‏
996 ‎‡2 BNE|XX1665378‏
996 ‎‡2 ISNI|0000000121226648‏
996 ‎‡2 SUDOC|185302580‏
996 ‎‡2 ISNI|0000000042693846‏
996 ‎‡2 LC|n 2004030505‏
996 ‎‡2 DNB|127910476‏
996 ‎‡2 LC|no2009002676‏
996 ‎‡2 BNE|XX1519861‏
996 ‎‡2 BNC|981061181946906706‏
996 ‎‡2 ISNI|0000000059458279‏
996 ‎‡2 PLWABN|9810659407205606‏
996 ‎‡2 DNB|1331567807‏
996 ‎‡2 DNB|1053337922‏
996 ‎‡2 BNE|XX929876‏
996 ‎‡2 LC|nr2002038604‏
996 ‎‡2 ISNI|0000000061033712‏
996 ‎‡2 RERO|A003083290‏
996 ‎‡2 BNE|XX1095763‏
996 ‎‡2 LC|n 2023184703‏
996 ‎‡2 CAOONL|ncf11200573‏
996 ‎‡2 NTA|235253987‏
996 ‎‡2 BNCHL|10000000000000000051519‏
996 ‎‡2 BNC|981058519499206706‏
996 ‎‡2 BNE|XX894401‏
996 ‎‡2 BNE|XX899351‏
996 ‎‡2 NTA|393574458‏
996 ‎‡2 RERO|A003754411‏
996 ‎‡2 J9U|987007324856305171‏
996 ‎‡2 DNB|1056636319‏
996 ‎‡2 ISNI|0000000475346102‏
996 ‎‡2 LC|no2008020184‏
996 ‎‡2 BNCHL|10000000000000000122544‏
996 ‎‡2 PTBNP|110122‏
996 ‎‡2 ISNI|0000000050414966‏
996 ‎‡2 BNE|XX1452273‏
996 ‎‡2 PLWABN|9810662600805606‏
996 ‎‡2 ISNI|0000000387487546‏
996 ‎‡2 BNCHL|10000000000000000031265‏
996 ‎‡2 BNE|XX971901‏
996 ‎‡2 BNE|XX1002707‏
996 ‎‡2 BNE|XX5377002‏
996 ‎‡2 BNE|XX896801‏
996 ‎‡2 LC|no2010029289‏
996 ‎‡2 DNB|1174817739‏
996 ‎‡2 BNCHL|10000000000000000054155‏
996 ‎‡2 BNC|981058511969406706‏
996 ‎‡2 SUDOC|113214855‏
996 ‎‡2 LC|no2014119090‏
996 ‎‡2 ISNI|0000000059280220‏
996 ‎‡2 BNE|XX4984909‏
996 ‎‡2 ISNI|0000000075643415‏
996 ‎‡2 BNCHL|10000000000000000801714‏
996 ‎‡2 ISNI|0000000031432026‏
996 ‎‡2 RERO|A019039088‏
996 ‎‡2 BNE|XX6379056‏
996 ‎‡2 LC|nr 94006306‏
996 ‎‡2 LC|n 83187351‏
996 ‎‡2 LC|n 88634915‏
996 ‎‡2 ISNI|0000000037699901‏
996 ‎‡2 BNC|981058608510906706‏
996 ‎‡2 BNCHL|10000000000000000199716‏
996 ‎‡2 NTA|160678528‏
996 ‎‡2 DNB|133100634‏
996 ‎‡2 KRNLK|KAC202146101‏
996 ‎‡2 ISNI|0000000059265522‏
996 ‎‡2 NKC|jo2013781216‏
996 ‎‡2 LC|no2003097035‏
996 ‎‡2 DNB|1192783638‏
996 ‎‡2 ISNI|000000011559804X‏
996 ‎‡2 SUDOC|266784763‏
996 ‎‡2 ISNI|0000000035218799‏
996 ‎‡2 LC|no2008151966‏
996 ‎‡2 BNE|XX1644502‏
996 ‎‡2 DNB|1078228736‏
996 ‎‡2 LC|n 95096878‏
996 ‎‡2 BNE|XX1062591‏
996 ‎‡2 BNE|XX5302893‏
996 ‎‡2 LC|no2004023248‏
996 ‎‡2 LC|no2015158029‏
996 ‎‡2 RERO|A002911883‏
996 ‎‡2 BNC|981058521573006706‏
996 ‎‡2 ISNI|0000000066598261‏
996 ‎‡2 ISNI|0000000060985228‏
996 ‎‡2 ISNI|0000000079994597‏
996 ‎‡2 ISNI|0000000498098834‏
996 ‎‡2 BNE|XX1771242‏
996 ‎‡2 SUDOC|184741580‏
996 ‎‡2 BNE|XX832839‏
996 ‎‡2 BNE|XX4937673‏
996 ‎‡2 BIBSYS|98003862‏
996 ‎‡2 SUDOC|177300515‏
996 ‎‡2 BNE|XX842260‏
996 ‎‡2 BNC|981058515200006706‏
996 ‎‡2 LC|n 2022033832‏
996 ‎‡2 PLWABN|9810631012405606‏
996 ‎‡2 BNE|XX6146663‏
996 ‎‡2 DNB|1228101191‏
996 ‎‡2 ISNI|0000000060214669‏
996 ‎‡2 SUDOC|164262369‏
996 ‎‡2 BNE|XX6248238‏
996 ‎‡2 BNF|18062323‏
996 ‎‡2 LC|no 00040694‏
996 ‎‡2 LC|ns2015002499‏
996 ‎‡2 LC|n 82111824‏
996 ‎‡2 ISNI|0000000377759114‏
996 ‎‡2 LC|no2019160294‏
996 ‎‡2 LC|n 2021052423‏
996 ‎‡2 DNB|135430526‏
996 ‎‡2 BNF|14221655‏
996 ‎‡2 ISNI|0000000071613016‏
996 ‎‡2 BNCHL|10000000000000000025826‏
996 ‎‡2 BNF|12491674‏
996 ‎‡2 BNE|XX1794782‏
996 ‎‡2 ISNI|0000000077817685‏
996 ‎‡2 ISNI|0000000078849654‏
996 ‎‡2 DNB|1272902854‏
996 ‎‡2 BNE|XX944261‏
996 ‎‡2 LC|n 93113052‏
996 ‎‡2 DNB|1057529508‏
996 ‎‡2 BNE|XX4772640‏
996 ‎‡2 DNB|1056386940‏
996 ‎‡2 ISNI|0000000416660927‏
996 ‎‡2 ISNI|0000000039797951‏
996 ‎‡2 DNB|1147233772‏
996 ‎‡2 BNE|XX5544372‏
996 ‎‡2 SUDOC|098614126‏
996 ‎‡2 LC|no 99069963‏
996 ‎‡2 BNE|XX848994‏
996 ‎‡2 ISNI|0000000059601944‏
996 ‎‡2 ISNI|000000011736997X‏
996 ‎‡2 DBC|87097991981424‏
996 ‎‡2 BNE|XX5842897‏
996 ‎‡2 LC|no2008039510‏
996 ‎‡2 DNB|12976907X‏
996 ‎‡2 NTA|33803207X‏
996 ‎‡2 LC|no2011056278‏
996 ‎‡2 CAOONL|ncf11705223‏
996 ‎‡2 LC|no2016138831‏
996 ‎‡2 BNE|XX5281510‏
996 ‎‡2 SUDOC|243756372‏
996 ‎‡2 BNE|XX5587634‏
996 ‎‡2 DNB|137451296‏
996 ‎‡2 BNC|981058509445806706‏
996 ‎‡2 ISNI|0000000045826907‏
996 ‎‡2 NTA|128786256‏
996 ‎‡2 ISNI|0000000122063801‏
996 ‎‡2 DNB|1159533857‏
996 ‎‡2 DNB|120300273‏
996 ‎‡2 PTBNP|609128‏
996 ‎‡2 ISNI|0000000496259390‏
996 ‎‡2 DNB|1057313378‏
996 ‎‡2 LC|nr 98004791‏
996 ‎‡2 ISNI|0000000029757868‏
996 ‎‡2 PLWABN|9812831570405606‏
996 ‎‡2 LC|no2010066306‏
996 ‎‡2 BNE|XX5673742‏
996 ‎‡2 SUDOC|242744133‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏